In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis: Building on a Base in Diabetes

Executive Summary

Aventis is looking to the diabetes market to boost future growth. Lantus, the company's novel once-a-day injectable insulin, will spearhead the move. But can Aventis use an injectable to break into the fast growing Type II segment?

You may also be interested in...



Promoting Me-Too Biologicals: Portfolio vs. Single Product Approach

Novo Nordisk's grand plan for pitting its new basal insulin Levemir against Aventis' dominant Lantus is to promote the product in the context of the company's broader insulin portfolio. Novo believes its portfolio approach should capture a greater overall share of the insulin space than Aventis with its one-size-fits-all strategy.

Zealand Deals Diabetes Drug to Aventis

Denmark's Zealand Pharma inked its second Big Pharma deal in as many months when it out-licensed its lead product, a Phase II diabetes treatment, to Aventis. Zealand's accelerated development of the product--which was tested immediately in patients, bypassing healthy volunteers--provided the firm with clinical proof of prinicple, on a budget.

A Coup for Nobex

Large pharma companies haven't set a high priority on developing new drug delivery formulations for their existing portfolios; nor have they been interested in macromolecule development. Thus, the strategic alliance forged in May between giant GSK and small drug-delivery firm Nobex is noteworthy. Not only is it one of the largest deals of its kind, but it also focuses on development of oral insulin for diabetic patients, which presents a challenge that few have attempted to overcome.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel